Pfizer ends Covid-19 trial with 95pct efficacy, to seek emergency-use authorisation


Modified 19 Nov 2020, 10:26 am

Pfizer Inc said final results from the late-stage trial of its Covid-19 vaccine show it was 95 percent effective, adding that it had the required two-months of safety data and would apply for emergency US authorisation within days.

The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunisation could be employed broadly around the world...

All Access Plan
starting from


per month
Subscribe Now
You can cancel anytime.
Get unlimited access to our articles on web and apps
Add comments to our articles
Bookmark articles to read later
We accept
Student or Senior Citizen? Get a special rateGroup / Institutional / Corporate Plans
Already Subscribed?
Sign In